DUBLIN--(BUSINESS WIRE)--The "Investigation Report on China Recombinant Factor VIII (rFVIII) Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.

There are approximately 400,000 to 1 million people with hemophilia in the world. Among them, there are about 100,000 to 200,000 patients in China. The registered hemophilia patients in China are less than 20,000 because most patients give up treatment due to expensive medical expenses. Those who lack coagulation factor VIII account for 80% to 85% of the hemophilia A patients. Currently, there is no cure for hemophilia, treatment for which is on the market are all alternatives. Coagulation factors are the main drugs.

In 1992, Baxter (Baxalta) publicized the first recombinant factor VIII(rFVIII). Because it has the same effects as natural coagulation factors without risks of blood-borne virus contamination, it is very popular in the market. The developed countries master mature technologies of recombinant coagulation factors. For example, recombinant coagulation factor VIII now has experienced four rounds of upgradation. The main manufacturers are Bayer, Baxalta, Pfizer, etc. By the end of 2020, no domestic recombinant coagulation factor VIII has been launched in China.

According to this market research, Recombinant Factor VIII developed rapidly after entering China. Its annual sales increased from less than CNY 6 million in 2009 to CNY481 million in 2019, and the CAGR reached 55% in 2009 to 2019. Currently, Recombinant Factor VIII sold on the Chinese market is all imported from Bayer, Baxalta and Pfizer. According to the sales value, Bayer accounted for nearly 70% of the Chinese market in 2019.

The analyst forecasts that with the development of China's economy, patients with hemophilia are more able to pay medical expenses. It is expected that the market scale of Recombinant Factor VIII in China will continue to increase from 2020 to 2024. After 2022, there is a possibility that Chinese companies may launch Recombinant Factor VIII.

Topics Covered:

• Development of Recombinant Factor VIII in China
• Sales volume and value of Recombinant Factor VIII in China
• Sales volume and value of Recombinant Factor VIII in regions of China
• Price of Recombinant Factor VIII in the Chinese market
• Key players of Recombinant Factor VIII in the Chinese market
• Research progress of Chinese companies on Recombinant Factor VIII
• Chinese market prospects on Recombinant Factor VIII from 2020 to 2024

Key Topics Covered:

1 Relevant Concept of Recombinant Factor VIII

1.1 Indication

1.2 Development in China

1.3 Patents and Government Approval on Drugs

2 Sales of Recombinant Factor VIII in China, 2015-2019

2.1 Sales Value of Recombinant Factor VIII in China

2.1.1 Overall Sales Value of Recombinant Factor VIII in China

2.1.2 Sales Value of Recombinant Factor VIII by regions of China

2.2 Sales Volume

2.2.1 Overall Sales Volume of Recombinant Factor VIII in China

2.2.2 Sales Volume of Recombinant Factor VIII by regions of China

2.3 Sales of Recombinant Factor ? by Dosage Forms in China

3 Major Manufacturers of Recombinant Factor VIII in China, 2015-2019

3.1 Market Share of Recombinant Factor VIII in China by Major Manufacturers

3.1.1 Market Share of Recombinant Factor VIII Manufacturers in China by Sales Value

3.1.2 Market Share of Recombinant Factor VIII Manufacturers in China by Sales Volume

3.2 Bayer

3.2.1 Enterprise Profile

3.2.2 Sales of Bayer's Recombinant Factor VIII in China

3.3 Baxalta

3.4 Pfizer

4 Prices of Recombinant Factor VIII in China, 2015-2020

4.1 Average Prices of Recombinant Factor VIII in China

4.1.1 Average Prices of Recombinant Factor VIII Capsules in China 2015-2019

4.1.2 Average Prices of Recombinant Factor VIII Tablets in China 2015-2019

4.2 Average Prices of Bayer' Recombinant Factor VIII (Kovaltry)

4.3 Average Prices of Baxalta's Recombinant Factor VIII (Adynovate)

4.4 Average Prices of Pfizer's Recombinant Factor VIII (Xyntha)

5 Market Prospects of Recombinant Factor VIII, 2020-2024

5.1 Forecast on Factors Influencing Development

5.2 Forecast on Market Size

5.3 Forecast on Development Trend

For more information about this report visit https://www.researchandmarkets.com/r/rsbg18

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900